Publicaciones (126) Publicaciones de ISABEL CASTREJÓN FERNÁNDEZ

2024

  1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

    Seminars in Arthritis and Rheumatism, Vol. 64

  2. Early identification of golimumab-treated patients with higher likelihood of long-term retention

    Frontiers in Immunology, Vol. 15

  3. Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  4. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases

  5. Macrophage re-programming by JAK inhibitors relies on MAFB

    Cellular and Molecular Life Sciences, Vol. 81, Núm. 1

  6. Opioids and fibromyalgia: frequency of use and factors associated with increased consumption in patients remitted to a tertiary care center

    BMC Musculoskeletal Disorders, Vol. 25, Núm. 1

  7. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

    Seminars in Arthritis and Rheumatism, Vol. 65

  8. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis

    European Journal of Clinical Investigation, Vol. 54, Núm. 2

  9. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

    Arthritis and Rheumatology, Vol. 76, Núm. 4, pp. 587-598

2023

  1. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  2. Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry (Arthritis Research & Therapy, (2023), 25, 1, (86), 10.1186/s13075-023-03045-3)

    Arthritis Research and Therapy

  3. Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey'

    Annals of the Rheumatic Diseases

  4. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

    The Lancet Regional Health - Europe, Vol. 33

  5. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  6. Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  7. Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence–Based Data Analyses of a National Multicenter Prospective Registry

    Arthritis Care and Research, Vol. 75, Núm. 1, pp. 115-124

  8. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

    Advances in Rheumatology, Vol. 63, Núm. 1

  9. Gender biases in Spanish rheumatology: Perception and facts

    Reumatologia Clinica, Vol. 19, Núm. 7, pp. 392-401

  10. Impact of ultrasound limitation to assess aortitis in patients with giant cell arteritis: comparative study with FDG-PET/CT

    RMD open, Vol. 9, Núm. 3

  11. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

    Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197